News
Zymeron Establishes MicroFAST Dx Division to Advance Rapid Diagnostic Technologies
(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced the formation of its new division, MicroFAST Dx. This strategic initiative builds upon Zymeron’s expertise in sample processing technologies to focus exclusively on advancing point-of-care and at-home diagnostic capabilities.
Zymeron Develops Molecularly Targeted Therapy to Treat Myelotoxicity
(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced that its myelotoxicity drug program is boosted by a $3.0M federal funding to advance its lead drug candidate in preclinical studies.
New Drug Implant Technology Offers Complete Infection Protection and Peace of Mind to Patients
(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced that it received multi-year funding from the Department of Defense to continue its development of a long-lasting antimalaria prophylactic drug.
Zymeron Relocated to the Frontier Campus, Research Triangle Park
(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced that it is relocated to the Frontier Campus Building 400, Research Triangle Park, NC. Frontier Building 400 provides renovated dynamic laboratory spaces for start-ups and small size companies with up to 50 employees.